# Conformal Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/conformal-medical

- Industry: Medical Devices & Equipment
- Headquarters: Nashua, US
- Website: www.conformalmedical.com
- Total disclosed funding: $114M
- Latest round: Series D (May 26, 2023)
- Investors on record: 3

## About

Conformal Medical, Inc. is a US-based company specializing in innovative solutions for patients with atrial fibrillation (Afib), focusing on minimizing stroke risk through advanced medical devices.Founded in 2016 and headquartered in Nashua, US, Conformal Medical develops devices aimed at reducing stroke risk in Afib patients.  The founders, Aaron Kaplan, Andy Levine, and Carol Devellian, have a history of innovation in the medical field and continue to lead the company with CEO James Reinstein at the forefront. In January 2026, W.L. Gore & Associates, Inc. agreed to acquire Conformal Medical, Inc. from Catalyst Health Ventures, Fidelity Investments, and Sprig Equity. The transaction is expected to be completed in February 2026, subject to customary closing conditions pending regulatory review.

Conformal Medical, Inc. specializes in innovative solutions for patients suffering from atrial fibrillation (Afib) and the associated risk of stroke. Their core product is the CLAAS® AcuFORM™ System, a foam device designed to occlude the left atrial appendage (LAA), effectively reducing the risk of stroke without the need for long-term oral anticoagulant therapy. This device is permanently implanted during a minimally invasive procedure, which utilizes a catheter placed through a small incision in the groin. The CLAAS System is currently undergoing clinical trials, including the Conformal Early Feasibility Study and the Prague Study, to ensure efficacy and safety. Conformal primarily targets healthcare providers, hospitals, and clinics in the United States and Europe, focusing on patients who require alternatives to anticoagulant medications due to the risks involved.

Conformal Medical generates revenue through the sale of its CLAAS® AcuFORM™ System, which is currently available for investigational use under regulatory oversight. The company engages with healthcare institutions and cardiology specialists, who may opt for the device as a treatment option for their patients with Afib. Revenue transactions are structured around direct sales to hospitals and clinics, where physicians can recommend the device for eligible patients. Pricing specifics for the CLAAS device are determined through negotiations with healthcare providers, reflecting standard practices in the medical device industry. The firm’s strategy includes forming partnerships with medical institutions to facilitate clinical trials and usage, enhancing customer engagement and building a solid client base within the healthcare sector.

## Funding rounds

- Series D, May 26, 2023, $35M — Sprig Equity
- Series C, Aug 6, 2020, $70M — Catalyst Health Ventures, Fidelity Investments
- Series B, Dec 3, 2018, $9M — Catalyst Health Ventures

## Investors

- Catalyst Health Ventures (https://capitalatlas.ai/funds/catalyst-health-ventures) — Series B, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Sprig Equity (https://capitalatlas.ai/funds/sprig-equity) — Series D